Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics [Yahoo! Finance]
MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
Company Research
Source: Yahoo! Finance
to a recent SEC Filing . This transaction has been part of the insider's trading activities over the past year, where the insider has sold a total of 60,000 shares and has not made any purchases. Warning! GuruFocus has detected 3 Warning Sign with MLTX. MoonLake Immunotherapeutics is a biopharmaceutical company focused on creating and developing innovative therapeutics for patients with inflammatory diseases and cancer. The company leverages its proprietary technology to target and modulate key cytokines involved in the pathogenesis of these serious diseases. The insider transaction history at MoonLake Immunotherapeutics indicates a pattern of insider activity over the past year. There have been 4 insider buys and 3 insider sells during this period. On the date of the insider's recent transaction, shares of MoonLake Immunotherapeutics were trading at $59.26 each, giving the company a market capitalization of $3.306 billion. The insider's decision to sell shares has contribut
Show less
Read more
Impact Snapshot
Event Time:
MLTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLTX alerts
High impacting MoonLake Immunotherapeutics - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MLTX
News
- MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions [Yahoo! Finance]Yahoo! Finance
- MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsBusiness Wire
- MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions GlobeNewswire
MLTX
Sec Filings
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form ARS
- 4/24/24 - Form DEF
- MLTX's page on the SEC website